Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelly Seibert

Optometrist Pittsburgh, PA Doctor of Optometry

NPI 1073911707 CMS profile 1287333

22 McIntyre Square Dr, Pittsburgh, PA 15237

Open in the dashboard

General payments

$4,514

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$750 paid to institutions, not to them · program year 2025

Through program year 2025, Kelly Seibert of Pittsburgh, PA is reported in the CMS Open Payments database as having received $4,514 across 119 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $750 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $394 16
2024 General $737 22
2023 General $1,080 31
2022 General $740 29
2021 General $295 12
2019 General $1,268 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Seibert
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Kelly Seibert were reported at $394. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Kelly Seibert Optometrist median Middle half National median
2019 $1,268 $159 $67–$371 $163
2020 $0 $72 $29–$165 $114
2021 $295 $125 $46–$292 $132
2022 $740 $162 $66–$374 $149
2023 $1,080 $177 $72–$406 $160
2024 $737 $188 $77–$427 $164
2025 $394 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,469 16 payments
  2. Sun Pharmaceutical Industries Inc. $538 25 payments
  3. Bausch & Lomb Americas Inc. $401 10 payments
  4. Oyster Point Pharma, Inc. $384 15 payments
  5. LKC Technologies, Inc. $333 4 payments
  6. Novartis Pharmaceuticals Corporation $292 15 payments
  7. Tarsus Pharmaceuticals, Inc. $218 8 payments
  8. Topcon Medical Systems, Inc. $188 2 payments
  9. TissueTech, Inc. $176 3 payments
  10. Dompe US, Inc. $145 3 payments
  11. Other $369 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,574 115 payments
  2. Travel and Lodging $939 4 payments
Products named General payments · program years 2019–2025
  1. DAILIES $644 6 payments
  2. AIR OPTIX $634 3 payments
  3. Cequa $538 25 payments
  4. TYRVAYA $384 15 payments
  5. XIIDRA $330 17 payments
  6. MIEBO $287 7 payments
  7. XDEMVY $218 8 payments
  8. PROKERA $156 2 payments
  9. AMNIOGRAFT $156 2 payments
  10. OXERVATE $145 3 payments
  11. Other $1,005 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

153

Median for Optometry: 120

Drug cost

$88,624

Median for Optometry: $8,864

Branded share of claims

56.9%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xdemvy Lotilaner Brand 16 $29,457
Xiidra Lifitegrast Brand 17 $19,896
Restasis Cyclosporine Brand 14 $19,880
Miebo Perfluorohexyloctane/Pf Brand 14 $10,636
Rocklatan Netarsudil Mesylat/Latanoprost Brand 14 $7,411
Latanoprost Generic 55 $721
Azelastine Hcl Generic 11 $334
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 12 $289

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$19,028

Medicare's payments for the services billed

Medicare patients

120

Average age 71

Services billed

429

73 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 54%
Diabetes 31%
Depression 27%
Ischemic heart disease 23%
Chronic kidney disease 22%
Osteoporosis 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $145
$145 16 —
Cequa
  • Sun Pharmaceutical Industries Inc. $64
$64 — —
OXERVATE
  • Dompe US, Inc. $44
$44 — —
IYUZEH
  • Thea Pharma Inc. $43
$43 — —
LUMIGAN
  • AbbVie, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record